SAN DIEGO--(BUSINESS WIRE)--Traversa Therapeutics, a preclinical-stage biopharmaceutical company developing novel RNA interference (RNAi) technologies, announced today the appointment of Curt W. Bradshaw, Ph.D., as the company’s Vice President of Research and Development. With extensive life science industry experience, Dr. Bradshaw provides Traversa with key leadership expertise to support the company's ongoing efforts to advance its RNAi technologies into the clinics.
"We have significantly strengthened Traversa with the addition of Dr. Bradshaw, whose unique and broad background is marked by achievement in both venture-backed and large pharmaceutical environments, supporting both preclinical and clinical therapeutic development of synthetic biologics. He has distinguished himself as a highly-regarded life science executive and we are excited to count him among the talented individuals that comprise our leadership team,” stated Hans A. Petersen, Traversa's President and Chief Executive Officer.
“Dr. Bradshaw is a stellar and exacting scientist. His biologics and chemistry background are directly applicable to advancing Traversa’s RNAi technologies through IND enabling studies and into the clinics. We are ecstatic that he has joined the Traversa team,” said Steven F. Dowdy, Ph.D., Traversa’s Scientific Founder.
Prior to joining Traversa, Dr. Bradshaw was the Vice President of Chemistry at CovX. Dr. Bradshaw is credited with co-inventing multiple clinical candidates, jointly establishing regulatory and intellectual property strategy, and expanding the technology base to novel classes of experimental therapeutics. Dr. Bradshaw was a key member of the CovX management team before, during and after the company’s acquisition by Pfizer. As a scientist and life science executive with nearly eighteen years of industry experience working with peptides, proteins, small molecules and bioconjugations, Dr. Bradshaw has proven expertise in bringing synthetic biologics to the clinic. His work has also included tenures with leading biotechnology and pharmaceutical companies Ligand Pharmaceuticals and Abbott Laboratories. While at Ligand and Abbott, Dr. Bradshaw developed drug substance manufacturing strategies and processes for numerous pre-clinical, clinical and approved pharmaceuticals.
About Traversa Therapeutics
Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The Company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Ovarian Cancer, Glioblastoma and Leukemia. The company was founded in La Jolla, California in 2006 based on technology developed by Steven F. Dowdy, Ph.D., and his research group at the Howard Hughes Medical Institute and the University of California San Diego relating to siRNA delivery technology and induction of RNA interference.